TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

BTK Inhibitors Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Delveinsight
BTK Inhibitors Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Over 30 pharmaceutical companies are developing BTK inhibitors targeting B-cell cancers, autoimmune disorders, and neurological conditions, with promising pipeline drugs in various clinical trial stages.

Insights
RHHBY   positive

Successfully met primary endpoint in Phase III trial for Fenebrutinib in multiple sclerosis treatment